Giulia Marzocchi
About
Giulia Marzocchi is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Giulia Marzocchi has authored 25 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 13 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Giulia Marzocchi's work include Multiple Myeloma Research and Treatments (13 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Giulia Marzocchi is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Giulia Marzocchi collaborates with scholars based in Italy, Norway and Netherlands. Giulia Marzocchi's co-authors include Michèle Cavo, Michele Baccarani, Elena Zamagni, Beatrice Anna Zannetti, Lucia Pantani, Carolina Terragna, Serena Rocchi, Katia Mancuso, Paola Tacchetti and Annalisa Pezzi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.
In The Last Decade
Giulia Marzocchi
22 papers receiving 319 citations
Peers
Giulia Marzocchi
Nikolaos Giannakoulas Greece
Gerald Gehbauer Germany
Miriam Hobbs United States
Yi‐Fang Chang Taiwan
Cécile Contin France
Nathalie Cheron France
Kerry Taylor United States
Liwei Fang China
Jason M. Melear United States
Ghaith Abu‐Zeinah United States
Citations per year, relative to Giulia Marzocchi Giulia Marzocchi (= 1×)
peers
Nikolaos Giannakoulas
Countries citing papers authored by Giulia Marzocchi
Since
Specialization
Citations
This map shows the geographic impact of Giulia Marzocchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Marzocchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Marzocchi more than expected).
Fields of papers citing papers by Giulia Marzocchi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Giulia Marzocchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Marzocchi. The network helps show where Giulia Marzocchi may publish in the future.
Co-authorship network of co-authors of Giulia Marzocchi
This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Marzocchi. A scholar is included among the top collaborators of Giulia Marzocchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Marzocchi. Giulia Marzocchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Terragna, Carolina, Marina Martello, Elena Zamagni, et al.. (2024). Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features. Nature Communications. 15(1). 1551–1551.
2.
Martello, Marina, Enrica Borsi, Lucia Pantani, et al.. (2024). Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients. Cancers. 16(17). 2929–2929.
3.
Marzocchi, Giulia, et al.. (2024). Land Grabbing and Development: The Case of Ethiopia. Journal of Asian and African Studies. 60(7). 4170–4187.
4.
Baldazzi, Carmen, Simona Luatti, Giulia Marzocchi, et al.. (2021). t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities. Cancer Genetics. 262-263. 35–39.
5.
Mancuso, Katia, Paola Tacchetti, Lucia Pantani, et al.. (2020). Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma. Bone Marrow Transplantation. 55(9). 1865–1867.
6.
Terragna, Carolina, Marina Martello, Lucia Pantani, et al.. (2016). A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs. Blood. 128(22). 2080–2080.
7.
Baldazzi, Carmen, Simona Luatti, Elisa Zuffa, et al.. (2016). Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes and Cancer. 55(4). 375–388.
8.
Tacchetti, Paola, Michèle Cavo, Serena Rocchi, et al.. (2016). Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leukemia & lymphoma. 57(9). 2058–2064.
9.
Zamagni, Elena, Cristina Nanni, Katia Mancuso, et al.. (2015). PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clinical Cancer Research. 21(19). 4384–4390.
10.
Zamagni, Elena, Cristina Nanni, Paola Tacchetti, et al.. (2014). Positron Emission Tomography With Computed Tomography–Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 14(3). e101–e104.
11.
Zamagni, Elena, Cristina Nanni, Francesca Gay, et al.. (2014). The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease. Blood. 124(21). 3371–3371.
12.
Bringhen, Sara, Lucia Pantani, Annalisa Pezzi, et al.. (2013). Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison. Blood. 122(21). 3344–3344.
13.
Martinelli, Giovanni, Gianantonio Rosti, Michele Baccarani, et al.. (2013). Working Party on CML analysis adverse prognostic influence on frontline imatinib therapy: a GIMEMA Additional chromosomal abnormalities in Philadelphia-positive clone:.
14.
Soverini, Simona, Alessandra Gnani, Caterina De Benedittis, et al.. (2011). Low-level Bcr–Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. Leukemia Research. 35(11). 1527–1529.
15.
Castagnetti, Fausto, Nicoletta Testoni, Simona Luatti, et al.. (2010). Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. Journal of Clinical Oncology. 28(16). 2748–2754.
16.
Cavo, Michèle, Elena Zamagni, Paola Tacchetti, et al.. (2009). Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. Clinical Lymphoma & Myeloma. 9. S51–S52.
17.
Soverini, Simona, Sabrina Colarossi, Alessandra Gnani, et al.. (2009). High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.. Blood. 114(22). 3262–3262.
18.
Arpinati, Mario, Gabriella Chirumbolo, Giulia Marzocchi, Michele Baccarani, & Damiano Rondelli. (2008). Increased Donor CD86+CD14+ Cells in the Bone Marrow and Peripheral Blood of Patients With Chronic Graft-Versus-Host Disease. Transplantation. 85(12). 1826–1832.
19.
Lemoli, Roberto M., Lucia Catani, Elisabetta Loggi, et al.. (2006). Mobilization of Bone Marrow‐Derived Hematopoietic and Endothelial Stem Cells After Orthotopic Liver Transplantation and Liver Resection. Stem Cells. 24(12). 2817–2825.
20.
Soverini, Simona, Giovanni Martinelli, Sabrina Colarossi, et al.. (2006). Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. Blood. 108(11). 836–836.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nikolaos Giannakoulas Breakdown of academic impact, for papers by Gerald Gehbauer Breakdown of academic impact, for papers by Miriam Hobbs Breakdown of academic impact, for papers by Yi‐Fang Chang Breakdown of academic impact, for papers by Cécile Contin Breakdown of academic impact, for papers by Nathalie Cheron Breakdown of academic impact, for papers by Kerry Taylor Breakdown of academic impact, for papers by Liwei Fang Breakdown of academic impact, for papers by Jason M. Melear Breakdown of academic impact, for papers by Ghaith Abu‐Zeinah